MedTrace Logo

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

NCT02499952 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-07-11

Study results available
· View outcomes & findings →

Summary

This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.

Conditions

  • Germ Cell Neoplasms
  • Testicular Neoplasms
  • Non Seminomatous Germ Cell Tumors
  • Mediastinal Neoplasms
  • Genital Neoplasms, Male
  • Genital Neoplasms, Female
  • Ovarian Neoplasms

Interventions

DRUG

Pembrolizumab

200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.

Sponsors & Collaborators

  • Hoosier Cancer Research Network

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Nasser Hanna, M.D.

    lead OTHER

Principal Investigators

  • Nasser Hanna, M.D. · Hoosier Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-13
Completion
2017-01-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499952 on ClinicalTrials.gov